<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309476</url>
  </required_header>
  <id_info>
    <org_study_id>R03018</org_study_id>
    <nct_id>NCT02309476</nct_id>
  </id_info>
  <brief_title>Sub-threshold Photocoagulation of Diabetic Macular Oedema</brief_title>
  <acronym>MEM</acronym>
  <official_title>Manchester Pascal Endpoint Management Laser Treatment of Diffuse Diabetic Macular Oedema (DMO): A Safety and Efficacy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Topcon Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Optos, PLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Manchester University NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Topcon's Endpoint Management (EM) is a new software from the Pascal® laser which allows us to&#xD;
      decrease the intensity of the burns (invisible burns) showing some landmarks with normal&#xD;
      intensity so the investigators can see the area which has been treated. The Pascal® system&#xD;
      with EM utilizes 577nm laser wavelength compared to the 532nm laser wavelength which was&#xD;
      utilized in previous Pascal® laser studies.&#xD;
&#xD;
      This study aims to demonstrate that 577nm Pascal® with EM has the same efficacy and&#xD;
      effectiveness as 532nm Pascal® in the treatment of diabetic macular oedema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic macular oedema (DMO) remains the most common cause of visual loss in diabetic&#xD;
      patients and affects around 29% of diabetic patients with 20 or more years of disease. The&#xD;
      Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated a significant benefit of&#xD;
      laser photocoagulation for the treatment of clinically significant macular oedema, reducing&#xD;
      the incidence of vision loss by approximately 50% at 3 years' follow-up.&#xD;
&#xD;
      The original ETDRS photocoagulation technique was adopted throughout the world and gradually&#xD;
      modified through the years. Despite the great improvements, loss of central vision,&#xD;
      paracentral scotoma and decreased color vision are some adverse events that can still occur,&#xD;
      mostly caused by the progressive enlargement of the laser scars consequent to the visible&#xD;
      burn of conventional laser photocoagulation.&#xD;
&#xD;
      New strategies have been developed for laser treatments that minimize the chorioretinal&#xD;
      damage while maintaining at least similar treatment efficacy.&#xD;
&#xD;
      And numerous clinical studies have been conducted with subvisible laser treatments. However,&#xD;
      the lack of a visible endpoint makes it difficult for the treating physician to know which&#xD;
      retinal areas have been treated in order to avoid retreatment and also to be confident that&#xD;
      the desired target tissue had been treated.&#xD;
&#xD;
      Topcon's Endpoint Management (EM) is a new software from the Pascal® laser which allows us to&#xD;
      decrease the intensity of the burns (invisible burns) showing some landmarks with normal&#xD;
      intensity so the investigators can see the area which has been treated.&#xD;
&#xD;
      The Pascal® system with EM utilizes 577nm laser wavelength compared to the 532nm laser&#xD;
      wavelength which was utilized in previous Pascal® laser studies.&#xD;
&#xD;
      This study aims to demonstrate that 577nm Pascal® with EM has the same efficacy and&#xD;
      effectiveness as 532nm Pascal®.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The PI decided to close the study early as patients with diffused macular oedema without any&#xD;
    previous treatment are uncommon.&#xD;
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of diabetic macular edema (central retinal thickness) within the 6 arms of the study</measure>
    <time_frame>12 months</time_frame>
    <description>To compare Green Pascal® laser and Yellow Pascal® laser using EM among 6 groups of participants using Pascal® laser with an application of full grid 112 burns in a single session</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in visual acuity (&gt; 10 letters or two lines in the ETDRS chart)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>increase in retinal sensitivity within the 6 arms of the study</measure>
    <time_frame>12 months</time_frame>
    <description>increase in retinal sensitivity will be assessed with fundus-related perimetry (microperimetry)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetic Macular Oedema</condition>
  <arm_group>
    <arm_group_label>PASCAL Laser, Green Laser 0.75</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Barely Visible Pascal laser grid using 532nm &quot;green&quot; wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PASCAL Laser, Green Laser 1 burn</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Barely Visible Pascal laser grid using 532nm &quot;green&quot; wavelength, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PASCAL Laser, 70% Yellow Laser 0.75</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pascal EM at 70% 577nm &quot;yellow&quot; laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the &quot;Landmark&quot; burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PASCAL Laser, 70% Yellow Laser 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pascal EM at 70% 577nm &quot;yellow&quot;, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the &quot;Landmark&quot; burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PASCAL Laser, 40% Yellow Laser 0.75</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pascal EM at 40% 577nm &quot;yellow&quot;, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the &quot;Landmark&quot; burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PASCAL Laser, 40% Yellow Laser 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pascal EM at 40% 577nm &quot;yellow&quot; laser grid, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the &quot;Landmark&quot; burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PASCAL Laser, Green Laser 0.75</intervention_name>
    <description>Barely Visible Pascal laser grid using 532nm &quot;green&quot; wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid</description>
    <arm_group_label>PASCAL Laser, Green Laser 0.75</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PASCAL Laser, Green Laser 1</intervention_name>
    <description>Barely Visible Pascal laser grid using 532nm &quot;green&quot; wavelength, 1 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid</description>
    <arm_group_label>PASCAL Laser, Green Laser 1 burn</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PASCAL Laser, 70% Yellow Laser 0.75</intervention_name>
    <description>Pascal EM at 70% 577nm &quot;yellow&quot; laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the &quot;Landmark&quot; burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid</description>
    <arm_group_label>PASCAL Laser, 70% Yellow Laser 0.75</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PASCAL Laser, 70% Yellow Laser 1</intervention_name>
    <description>Pascal EM at 70% 577nm &quot;yellow&quot; laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the &quot;Landmark&quot; burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid</description>
    <arm_group_label>PASCAL Laser, 70% Yellow Laser 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PASCAL Laser, 40% Yellow Laser 0.75</intervention_name>
    <description>Pascal EM at 40% 577nm &quot;yellow&quot; laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the &quot;Landmark&quot; burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid</description>
    <arm_group_label>PASCAL Laser, 40% Yellow Laser 0.75</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PASCAL Laser, 40% Yellow Laser 1</intervention_name>
    <description>Pascal EM at 40% 577nm &quot;yellow&quot; laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the &quot;Landmark&quot; burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid</description>
    <arm_group_label>PASCAL Laser, 40% Yellow Laser 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient-eligibility&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. Older than 18 years of age&#xD;
&#xD;
          2. Male or female patients with diabetes mellitus type I or type 2 who meet the WHO or&#xD;
             ADA criteria for diabetes&#xD;
&#xD;
          3. Able to give informed consent&#xD;
&#xD;
        Study Eye eligibility&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. ETDRS visual acuity equivalent to 35 letters or better (Snellen equivalent 20/200 or&#xD;
             better)&#xD;
&#xD;
          2. The patient must have non-proliferative diabetic retinopathy (NPDR) with diffuse&#xD;
             macular oedema&#xD;
&#xD;
          3. Mean average central retinal thickness at least 300 microns as measured by Deep Range&#xD;
             Imaging Optical Coherence Tomography (DRI -OCT) scans&#xD;
&#xD;
          4. Adequate pupil dilatation and clear media to perform wide-field colour, red-free&#xD;
             imaging and fundus fluorescein angiography (WF-FFA), wide-field fundus&#xD;
             autofluorescence imaging (WF-AF) and DRI-OCT&#xD;
&#xD;
          5. Ability to perform accurate Humphmrey visual field test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient-eligibility&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. History of chronic renal failure or renal transplant for diabetic nephropathy&#xD;
&#xD;
          2. Recent (last 6 months) or on-going poor glycaemic control. H1Ac greater than 10.0mg/dL&#xD;
&#xD;
          3. Creatinine greater than 1.2 mg/dL&#xD;
&#xD;
          4. HDL equal to or greater than 40 mg/dL&#xD;
&#xD;
          5. Uncontrolled hypertension. Blood pressure greater or equal to 180/110 mmHg&#xD;
&#xD;
          6. Patient is unavailable for follow-up visits&#xD;
&#xD;
          7. Pregnant women or breast-feeding females&#xD;
&#xD;
        Study Eye eligibility&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Lens opacity that could influence vision and results&#xD;
&#xD;
          2. Proliferative Diabetic Retinopathy.&#xD;
&#xD;
          3. Any surgical or non-retinal laser treatment to the study eye within 2 months&#xD;
&#xD;
          4. Narrow drainage angles with raised intraocular pressure and angle closure glaucoma.&#xD;
&#xD;
          5. Planned YAG peripheral iridotomy&#xD;
&#xD;
          6. Previous retinal laser photocoagulation, intraocular drug therapy, or macular laser&#xD;
             treatment to treatment eye in last year&#xD;
&#xD;
          7. Vitreomacular traction determined clinically and / or OCT, which in the opinion of the&#xD;
             investigator, contributes to macular edema (associated or cause a detachment of the&#xD;
             fovea) and prevents the improvement with treatment.&#xD;
&#xD;
          8. Atrophy / scar / fibrosis involving the center of the macula, including evidence of&#xD;
             atrophy treated with laser within 200 microns of the FAZ.&#xD;
&#xD;
          9. Any previous ocular condition that may be associated with a risk of macular edema&#xD;
&#xD;
         10. Important known allergies to sodium fluorescein dye used in angiography.&#xD;
&#xD;
        12. Active lid or adnexal infection 13. Planned intra-ocular surgery within one year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo Stanga</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester Royal Eye Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Manchester Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Manchester University NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Emma Columbine</investigator_full_name>
    <investigator_title>Professor Paulo Stanga</investigator_title>
  </responsible_party>
  <keyword>diffuse diabetic macular oedema</keyword>
  <keyword>Pascal</keyword>
  <keyword>Laser</keyword>
  <keyword>DMO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

